| Somatotropin deficiency

Skytrofa vs Genotropin

Side-by-side clinical, coverage, and cost comparison for somatotropin deficiency.

Deep comparison between: Skytrofa vs Genotropin with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsGenotropin has a higher rate of injection site reactions vs Skytrofa based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Genotropin but not Skytrofa, including UnitedHealthcare

Category

Skytrofa

Genotropin

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassPegylated growth hormone prodrug

RouteSC injection

Frequency6-7 times weekly

ClassRecombinant human growth hormone

Indications

Somatotropin deficiency

Somatotropin deficiency
Prader-Willi Syndrome
Growth failure
Turner Syndrome
Growth Disorders

Dosing

Somatotropin deficiency (pediatric) 0.24 mg/kg body weight SC once weekly; individualize and titrate based on response.

Somatotropin deficiency (adult) Starting dose 0.7-2.1 mg SC once weekly based on age and concomitant oral estrogen use; titrate monthly based on clinical response and/or IGF-1 concentration; maximum 6.3 mg once weekly.

Somatotropin deficiency (pediatric) 0.16 to 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Prader-Willi Syndrome 0.24 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Turner Syndrome 0.33 mg/kg/week SC, divided into 6-7 subcutaneous injections.

Growth Disorders Up to 0.47 mg/kg/week SC (idiopathic short stature), divided into 6-7 subcutaneous injections.

Growth failure Up to 0.48 mg/kg/week SC (born small for gestational age), divided into 6-7 subcutaneous injections.

Somatotropin deficiency (adult) Non-weight based: starting ~0.2 mg/day SC (range 0.15-0.30 mg/day), titrated by 0.1-0.2 mg/day increments; weight based: starting up to 0.04 mg/kg/week SC, titrated to up to 0.08 mg/kg/week.

Contraindications

Acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Hypersensitivity to somatropin or any excipient in SKYTROFA
Closed epiphyses in pediatric patients
Active malignancy
Active proliferative or severe non-proliferative diabetic retinopathy
Prader-Willi syndrome in pediatric patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment

Acute critical illness due to complications following open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
Prader-Willi syndrome with severe obesity, history of upper airway obstruction or sleep apnea, or severe respiratory impairment
Active malignancy
Known hypersensitivity to somatropin or any excipient
Active proliferative or severe non-proliferative diabetic retinopathy
Closed epiphyses (for growth promotion in pediatric patients)

Drug Interactions

196View drug interactions

267View drug interactions

Adverse Reactions

Most common (>= 5%) Viral infection, pyrexia, cough, nausea and vomiting, hemorrhage, diarrhea, abdominal pain, arthralgia and arthritis (pediatric); edema, central hypothyroidism (adult)

Serious Increased mortality in acute critical illness, severe hypersensitivity, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, progression of preexisting scoliosis, pancreatitis, lipoatrophy, sudden death in Prader-Willi syndrome pediatric patients

Postmarketing Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema, osteonecrosis in pediatric patients

Most common (>=5%) Peripheral swelling, arthralgia, upper respiratory infection, pain in extremities, peripheral edema, paresthesia, headache, stiffness of extremities, fatigue (reported in adult GHD clinical trials at or above 5% threshold)

Serious Increased mortality in acute critical illness, fatalities in Prader-Willi syndrome, neoplasms, glucose intolerance and diabetes mellitus, intracranial hypertension, severe hypersensitivity, fluid retention, hypoadrenalism, hypothyroidism, slipped capital femoral epiphysis, scoliosis progression, otitis media and cardiovascular disorders in Turner syndrome, pancreatitis

Postmarketing Serious systemic hypersensitivity reactions including anaphylaxis and angioedema, leukemia, new-onset type 2 diabetes mellitus, slipped capital femoral epiphysis, osteonecrosis/avascular necrosis, carpal tunnel syndrome

Pharmacology

Lonapegsomatropin-tcgd is a pegylated prodrug of somatropin that releases active growth hormone via autocleavage of the TransCon linker; somatropin binds the growth hormone (GH) receptor, driving IGF-1-mediated and direct effects including chondrocyte differentiation and proliferation, hepatic glucose output, protein synthesis, lipolysis, and skeletal growth at the epiphyses of long bones.

Somatropin, a recombinant human growth hormone therapeutically equivalent to pituitary-derived GH, stimulates linear growth in pediatric patients through effects on epiphyseal plates, normalizes IGF-I concentrations in GHD and Prader-Willi syndrome, and in adults reduces fat mass and increases lean body mass with favorable lipid metabolic changes.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Skytrofa